These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 26039379)

  • 21. Pharmacokinetic considerations for community-based dosing of nasal naloxone in opioid overdose in adults.
    Dale O
    Expert Opin Drug Metab Toxicol; 2022 Mar; 18(3):203-217. PubMed ID: 35500297
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of opioid overdose during the COVID-19 pandemic: The role of relapse, treatment access and nonprescribed buprenorphine/naloxone.
    Kline A; Williams JM; Steinberg ML; Mattern D; Chesin M; Borys S; Chaguturu V
    J Subst Use Addict Treat; 2023 Jun; 149():209028. PubMed ID: 37003539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study.
    McDonald R; Lorch U; Woodward J; Bosse B; Dooner H; Mundin G; Smith K; Strang J
    Addiction; 2018 Mar; 113(3):484-493. PubMed ID: 29143400
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Take-Home Naloxone for the Emergency Interim Management of Opioid Overdose: The Public Health Application of an Emergency Medicine.
    Strang J; McDonald R; Campbell G; Degenhardt L; Nielsen S; Ritter A; Dale O
    Drugs; 2019 Sep; 79(13):1395-1418. PubMed ID: 31352603
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Opioid overdose prevention and naloxone rescue kits: what we know and what we don't know.
    Kerensky T; Walley AY
    Addict Sci Clin Pract; 2017 Jan; 12(1):4. PubMed ID: 28061909
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful bystander-administered intranasal naloxone reversal of opioid overdose between two veterans: A case report.
    Ouyang S; Moore T
    Ment Health Clin; 2017 Nov; 7(6):287-289. PubMed ID: 29955536
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Take -home naloxone rescue kits following heroin overdose in the emergency department to prevent opioid overdose related repeat emergency department visits, hospitalization and death- a pilot study.
    Papp J; Vallabhaneni M; Morales A; Schrock JW
    BMC Health Serv Res; 2019 Dec; 19(1):957. PubMed ID: 31829228
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Telephone-based opioid overdose education and naloxone distribution (OEND) pharmacy consult clinic.
    Szydlowski EM; Caruana SS
    Subst Abus; 2018; 39(2):145-151. PubMed ID: 31032747
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modeling of overdose and naloxone distribution in the setting of fentanyl compared to heroin.
    Coffin PO; Maya S; Kahn JG
    Drug Alcohol Depend; 2022 Jul; 236():109478. PubMed ID: 35588609
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Saving Lives: The Veterans Health Administration (VHA) Rapid Naloxone Initiative.
    Oliva EM; Richardson J; Harvey MA; Bellino P
    Jt Comm J Qual Patient Saf; 2021 Aug; 47(8):469-480. PubMed ID: 34330409
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Two cases of intranasal naloxone self-administration in opioid overdose.
    Green TC; Ray M; Bowman SE; McKenzie M; Rich JD
    Subst Abus; 2014; 35(2):129-32. PubMed ID: 24821348
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Urban, individuals of color are impacted by fentanyl-contaminated heroin.
    Rhodes B; Costenbader B; Wilson L; Hershow R; Carroll J; Zule W; Golin C; Brinkley-Rubinstein L
    Int J Drug Policy; 2019 Nov; 73():1-6. PubMed ID: 31330274
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-Effectiveness of Take-Home Naloxone for the Prevention of Overdose Fatalities among Heroin Users in the United Kingdom.
    Langham S; Wright A; Kenworthy J; Grieve R; Dunlop WCN
    Value Health; 2018 Apr; 21(4):407-415. PubMed ID: 29680097
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Perceptions about fentanyl-adulterated heroin and overdose risk reduction behaviors among persons seeking treatment for heroin use.
    Stein MD; Kenney SR; Anderson BJ; Bailey GL
    J Subst Abuse Treat; 2019 Sep; 104():144-147. PubMed ID: 31370978
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An increase in per-patient naloxone requirements in an opioid epidemic.
    Birmingham LE; Nielson JA
    Am J Emerg Med; 2017 Dec; 35(12):1958-1959. PubMed ID: 28633907
    [No Abstract]   [Full Text] [Related]  

  • 36. Abuse of fentanyl: An emerging problem to face.
    Kuczyńska K; Grzonkowski P; Kacprzak Ł; Zawilska JB
    Forensic Sci Int; 2018 Aug; 289():207-214. PubMed ID: 29902699
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Equipping an urban hospital police and security team with Narcan.
    Driscoli J; Michelman B
    J Healthc Prot Manage; 2016 Oct; 32(2):1-4. PubMed ID: 29638270
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Opioid Overdose Outbreak - West Virginia, August 2016.
    Massey J; Kilkenny M; Batdorf S; Sanders SK; Ellison D; Halpin J; Gladden RM; Bixler D; Haddy L; Gupta R
    MMWR Morb Mortal Wkly Rep; 2017 Sep; 66(37):975-980. PubMed ID: 28934186
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical provision of improvised nasal naloxone without experimental testing and without regulatory approval: imaginative shortcut or dangerous bypass of essential safety procedures?
    Strang J; McDonald R; Tas B; Day E
    Addiction; 2016 Apr; 111(4):574-82. PubMed ID: 26840916
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Challenges with take-home naloxone in reducing heroin mortality: a review of fatal heroin overdose cases in Victoria, Australia.
    Stam NC; Gerostamoulos D; Smith K; Pilgrim JL; Drummer OH
    Clin Toxicol (Phila); 2019 May; 57(5):325-330. PubMed ID: 30451007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.